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SAMMANFATTNING 
Osteoartrit är en vanlig sjukdom hos våra domesticerade hundar och estimeras drabba tjugo 
procent av alla hundar över ett år. Tillståndet förknippas med kronisk smärta och nedsatt 
rörelsefunktion. Som behandling används ofta icke-steroida antiinflammatoriska läkemedel, så 
kallade NSAIDs med syfte att lindra smärtan och därmed förbättra livskvaliten. Även om 
NSAIDs har visat sig ha en stark smärtlindrande effekt associeras behandlingen även med ett 
flertal bieffekter som kan ge upphov till allvarliga skador relaterade till bland annat 
magtarmkanal och njurar. Dessutom är NSAIDs säkerhetsprofil för långtidsbehandling hos 
osteoartrit på hund ännu ej klarlagd.  
Naturläkemedlena glukosmin- och kondroitinsulfat är idag ett vanligt supplement som ofta ges 
via maten. Dessa sägs kunna bromsa brosknedbrytningen i leden samtidigt som de stimulerar 
syntes av broskets extracellulära matrix (ECM). De sägs även ha en smärtlindrande verkan 
samtidigt som själva återuppbyggandet av leden också verkar smärtlindrande på sikt. De 
faktiska effekterna är dock omdebatterade och studier visar på olika resultat.  NSAIDs tycks 
generellt nå bättre smärtlindrande effekt på kortare tid vilket gör att det finns skäl att ifrågasätta 
glukosamin- och kondroitinsulfat som enda behandling. 
Fysisk rehabilitering och viktkontroll är också viktiga i behandlingen av osteoartrit hos hund. 
Överviktiga hundar löper större risk att drabbas av osteoartrit och den extra vikten försämrar 
även sjukdomstillståndet. En studie visade att hundar som fick begränsad fodergiva var mindre 
exponerade för utvecklandet och fortskridandet av osteoartrit.  
Hundens situation bör även beaktas ur ett etiskt- och djurvälfärdsperspektiv. Osteoartrit är en 
livslång sjukdom och gränsen mellan när djurets lidande överskrider den effekt som nås med 
behandling är diffus. Enligt Djurskyddslagen skall ”djur skyddas mot onödigt lidande och 
sjukdom samt hållas och skötas på ett sådant sätt att det främjar deras hälsa och ger dem 
möjlighet att bete sig naturligt”. Hundar med osteoartrit har begränsad rörelseförmåga och är 
utsatta för smärtexponering till varierande grad. Det kan hända att vi bygger upp tolerans mot 
det tillstånd som hundar med osteoartrit befinner sig i och fortsätter behandla i lägen där det 
inte kan anses etiskt försvarsbart.  
Syftet med denna uppsats är att diskutera behandling av smärta hos hundar med osteoartrit. 
Vilka risker finns det vid behandling med NSAIDs och skulle glukosamin- och kondroitinsulfat 
kunna vara ett alternativ? Vidare kommer vikten av viktkontroll att behandlas och den slutliga, 
till viss del obekväma frågan att ställas, när ska man respektive när ska man inte behandla? 
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SUMMARY 
Osteoarthritis is a common disease in domesticated dogs and is estimated to affect twenty 
percent of all dogs over one year of age. The condition is associated with chronic pain and 
lameness. Non steroid anti-inflammatory drugs, also known as NSAIDs, are often used in the 
treatment of osteoarthritis and are known to relieve the pain and thereby improve the quality of 
life for those affected. Although NSAIDs are known to have a strong analgesic effect, the drugs 
are also associated with several adverse effects which can cause severe damage for example in 
the gastrointestinal tract and the kidneys. Furthermore NSAIDs safety profile for long-term 
treatment of osteoarthritis in dogs, is not yet fully elucidated.  
The nutraceuticals glucosamine- and chondroitin sulphate are today common supplements to 
dogs, often mixed with the food. These are said to be able to slow down cartilage destruction 
in the joint while stimulating the synthesis of cartilage extracellular matrix (ECM). They are 
also said to have an analgesic effect. Its actual impact, however, is controversial and the two 
studies presented in this paper show somewhat different results. Both, however, agree that 
NSAIDs reach higher analgesic effect in less time, which means that there are reasons to 
question glucosamine and chondroitin sulphate as the only treatment in dogs with osteoarthritis. 
Furthermore, physical rehabilitation and weight management play important part in the 
development and progression of osteoarthritis in dogs. Overweight dogs are more likely to 
suffer from osteoarthritis and the excessive weight also impairs the illness. One study showed 
that dogs who received limited amount of food over lifetime were less exposed to the 
development and progression of osteoarthritis than dogs in the control group.  
It is important to care for the dogs even from an ethical- and animal welfare point of view. 
Osteoarthritis is a lifelong disease and the limit between when the animal's suffering exceeds 
the effect that can be reached with treatment, is diffuse. According to the Swedish Animal 
Welfare Act, “animals are to be treated well and to be protected from unnecessary suffering 
continuing to be managed in such a way that it promotes their health and allows them to behave 
naturally”. Dogs with osteoarthritis have limited mobility and are exposed to pain to varying 
degrees. There is a risk that we build up tolerance to the state of dogs with osteoarthritis and 
continue to treat them although it can’t be considered ethically defensible. 
The purpose of this thesis is to discuss the treatment of pain in dogs with osteoarthritis. What 
risks are there in the treatment with NSAIDs and could glucosamine- and chondroitin sulphate 
be an option? Further, the importance of weight management will be addressed and the final, 
yet uncomfortable question to be asked, to treat or not to treat? 
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INTRODUCTION 
Osteoarthritis is a painful condition that in a survey of two hundred veterinarians, has been 
estimated to affect as much as twenty percent of the dog population over one year of age (Pfizer 
Animal Health, 1996). There are numerous of strategies on how to treat osteoarthritis in dogs. 
They all have similar goals including giving adequate analgesic effect, preserve joint mobility 
by slowing down disease progression, and for some, even to improve the pathological condition 
by restoring the joint (McLaughlin, 2000). 
However up till today there is no treatment that completely cure affected (KuKanich et al., 
2012). One of the main treatment methods is NSAIDs that act anti-inflammatory and analgesic 
but there is uncertainty about the safety profile, particularly in the long term. Treated dogs have 
been seen with adverse effects in the form of gastrointestinal-, kidney-, liver- and 
cardiovascular damage, to name the most common (KuKanich et al., 2012). Henceforth 
NSAIDs just relieve the pain that dogs with osteoarthritis experience, without demonstrably 
improving the medical condition. 
New methods have become popular in the treatment of osteoarthritis in dogs and one of them 
is the nutraceutical glucosamine, often combined with chondroitin sulphate. These are said to 
modulate the state of the disease whilst they also possess analgesic effects (Henrotin et al., 
2005). 
As the dog gets older the joints successively wear out and this, along with obesity, have a major 
impact on the risk of developing osteoarthritis. Weight management and physical rehabilitation 
are considered cornerstones in the treatment by improving function and reducing the stress on 
the joints (Rychel, 2010). 
Although the treatment methods are many, ultimately one may still end up in a dead end. The 
dog's suffering must be weighed against the effect you can actually achieve with the treatment, 
and sometimes it is ethically questionable how long the treatment should go on for. 
The purpose of this thesis is to discuss the treatment of pain in dogs with osteoarthritis. What 
risks are there in the treatment with NSAIDs and could glucosamine- and chondroitin sulphate 
be an option? Further, the importance of weight management will be addressed and the final, 
yet uncomfortable question to be asked, to treat or not to treat? 
MATERIALS AND METHODS  
The search for literature emanated from the databases Web of Science, PubMed and Google 
Scholar. The keywords used for the searches were (dog OR canine), (osteoarthritis OR arthritis), 
(NSAIDs OR COX), (glucosamine AND chondroitin), (pain OR nociceptive), (weight 
management AND physical rehabilitation). These were used in various combinations to sort 
out and collect a number of articles. Some articles have also been found in reference lists of 
already chosen articles. 
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LITERATURE OVERVIEW  
What is pain? 
The official definition describes pain as “an unpleasant sensory and emotional experience, 
associated with actual or potential tissue damage, or described in terms of such damage” 
(International Association for the Study of Pain, IASP; Läkemedelsboken, 2016). In other 
words, pain involves both sensory and emotional components and reflects, not only how the 
pain feels, but also how it makes you feel. Pain is an individual experience and can further be 
divided into nociceptive and neuropathic pain (Mathews et al., 2014). 
Nociceptive and Neuropathic pain 
Nociceptive pain usually derives from tissue damage where nociceptors localised on free nerve 
endings, sometimes referred to as pain receptors, respond to chemical, thermal and mechanical 
stimulus. In addition there are algogenic substances such as histamine, bradykinin and 
prostaglandins, which through peripheral sensitization, enable and enhance pain perception 
(Attring et al., 2002). 
The peripheral nerves consist of myelinated and unmyelinated nerve fibres, propagating nerve 
impulses. They are headed to the dorsal horn of the spinal cord where a switch is made to 
ascending pathways, mainly to the thalamus. In the thalamus yet another switch is made to the 
sensory cortex and the limbic system. It is in the limbic system where both physical and mental 
pain become conscious pain (Attring et al., 2002). 
Neuropathic pain is initiated or caused by a primary lesion or dysfunction in the nervous system 
(The International Association for the Study of Pain, IASP; Läkemedelsboken, 2016). It is a 
chronic type of pain which lesions can be widely varied and difficult to diagnose. The thing 
they have in common is all originate directly from the nervous system (Grubb, 2010). 
Acute and Chronic pain 
Pain can also be divided into acute and chronic. Acute pain is most often associated with tissue 
damage and usually occurs in dogs after a trauma, surgery, medical complications, infections 
or inflammatory diseases. The duration can vary from a few hours to several days. There is no 
subtle line where acute pain becomes chronic but traditionally pain that has been ongoing for 
more than three months is considered chronic pain (Mathews et al., 2014). 
Osteoarthritis is a complex chronic condition involving nociceptive- and possibly neuropathic 
pain. According to Dimitroulas et al. (2014), a neuropathic pain component may be 
predominant in individuals with minor joint changes. 
Osteoarthritis in dogs 
Johnston (1997) describes osteoarthritis as a syndrome rather than a single disease consisting 
of progressive and degenerative pathological changes regarding the synovial joint leading to 
pain and disability. A more detailed description made by Goldring & Goldring (2007) 
characterizes the condition as degeneration of the articular cartilage, changes in the peri-
articular and subchondral bone with osteophyte formation and limited intraarticular 
inflammation with synovitis. 
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In dogs osteoarthritis occurs mainly secondary to congenital or acquired musculoskeletal 
disorders causing abnormal force on normal joint or normal force on abnormal joint (Henrotin 
et al., 2005; Johnston, 1997). Examples are stress on joints due to obesity or excessive exercise 
(Elliot et al., 2007). 
Osteoarthritis occurs in all age groups but older dogs are predisposed and an estimated twenty 
percent of all dogs over 1 year of age, are affected (Pfizer Animal Health, 1996). Few 
epidemiological studies have been carried out on osteoarthritis in dogs in comparison to humans 
and the prevalence in different species remains unknown (Henrotin et al., 2005). However Elliot 
et al. (2007) stated that 45% of the large breed dogs, such as German Shepherd and Labrador 
Retriever, have osteoarthritis and are generally are more susceptible due to being genetically 
predisposed. Large breed dogs also seem to have a higher rate of orthopaedic diseases 
eventually progressing into osteoarthritis.  
Goldring & Goldring (2007) have investigated the source of pain in osteoarthritis and 
considered the synovial products formed during inflammation as potential contributors to 
symptoms of pain. Painful stimuli include neuropeptides such as substance P and damaged 
synovial cells releasing pro-inflammatory cytokines and producing prostanoids (Goldring & 
Goldring, 2007; Elliot et al., 2007). These are detected by afferent sensory nerves, nociceptors, 
which can be found in the joint capsule, ligaments, periosteum and subchondral bone. When 
the limits of physiological articulation are exceeded, the action potentials increase considerably 
and the central nervous system detects this as pain (Goldring & Goldring, 2007). 
Anti-inflammatory and analgesic drugs 
NSAIDs 
Ever since the first Nonsteroidal anti-inflammatory drug (NSAID) aspirin was marketed in 
1899, NSAIDs have been used to treat chronic pain and are commonly used to treat 
osteoarthritis in dogs. Their rapid efficacy when it comes to alleviating pain are making them 
popular although they are associated with, at times, serious adverse effects ( Innes et al., 2010a). 
Mechanism of action 
The group of drugs aim to inhibit the cyclooxygenase (COX) enzyme which catalyses the 
conversion of arachidonic acid in the prostaglandin- and thromboxane synthesis (Innes et al., 
2010b). By doing that, the so called COX-inhibitors, achieve anti-inflammatory, antipyretic and 
analgesic characteristics. The anti-inflammatory and analgesic ability of NSAIDs are most 
likely derived mainly from the inhibition of prostaglandin E2, (PGE2), whose concentrations 
have shown elevated in synovial fluid from osteoarthritic joints (Innes et al., 2010a). Both PGE2 
and prostacyclin I2 (PGI2), possess pro-inflammatory characteristics dilating arterioles and 
mediating pain perception through histamine and bradykinin. PGE2 further sensitize central and 
peripheral nociceptors (Bergh & Budsberg, 2005). 
The COX enzyme can it its turn be subdivided into two isoforms, cyclooxygenase-1 (COX-1) 
and -2 (COX-2). They are catalysing synthesis of different prostanoids having numerous of 
physiological effects. The most important being summarized in Table 1.  
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To distinguish COX-1 and COX-2 one could say that COX-1 is expressed in almost all tissues 
for the maintenance of normal physiological functions. The number of COX-2 however, tends 
to increase during inflammation under influence of pro-inflammatory cytokines. The level of 
COX-2, for example, increases in endothelial cells, chondrocytes, synovial cells, osteoblasts 
and macrophages during osteoarthritis. Although this division may appear distinct, the complete 
correlation between the two COX isoforms, is much more complex (Innes et al., 2010a). COX-
2 is for example, constantly present in the kidney, gastrointestinal tract, neural- and 
reproductive system, necessary for normal function of the tissues (Lomas & Grauer, 2015). 
The distinction between “good” and “bad” is thus subtle when it comes to COX inhibition. The 
general belief today is that NSAIDs who selectively inhibit only COX-2, generate analgesia 
with less adverse events, especially concerning the gastrointestinal tract, than those of COX-1 
inhibition. These drugs, allowing continued PGE2 protective production through COX-1, are 
called cyclogenase-2 inhibitors (COXIBs) ( Innes et al., 2010a; KuKanich et al., 2012). 
Adverse effects NSAIDs 
The number of adverse drug effects associated with NSAIDs is higher than for any other drug 
used for pets (The Federal Drug Administration Centre for Veterinary Medicine, 2008). 
Therefore, it is of vital importance to understand the NSAIDs´ mechanisms of action. COX-1 
and -2 inhibition possess different therapeutic possibilities since they, to various degrees, 
negatively affect organs. The most common being the gastrointestinal tract, the kidneys, the 
liver and cardiovascular system (KuKanich et al., 2012). The two most common will be 
addressed in this thesis. 
Gastrointestinal tract 
The most talked about adverse effects regards the gastrointestinal tract where both COX-1 and 
COX-2 are normally expressed in dogs. PGE2 and PGI2 both help protect the organ, increasing 
blood flow and mucus- and bicarbonate production at the same time as they slow down acid 
secretion. Hence inhibition of these enzymes or direct irritation of the mucosa after 
administration of the drug, can lead to injuries causing gastritis, enteritis, ulceration and 
perforation. Showing clinical signs as diarrhoea and/or vomiting (KuKanich et al., 2012). 
TABLE 1: Showing the prostanoids synthetized in the COX-pathways and their effects 
COX-1 Prostaglandin E2 (PGE2) -Vasodilation, 
-Sensitization of both central and peripheral 
nociceptors, 
-Numerous of gastrointestinal effects protecting the 
stomach, 
-Increase sodium and water excretion and change 
chloride transport in the kidneys.  
-Stimulate renin secretion altering renal blood flow in 
dogs 
Thromboxane A2 (TXA2) -Increased platelet clumping 
COX-2 Prostaglandin E2 (PGE2) -See COX-1 
Prostacyclin (PGI2) -Vasodilation, 
- Decreased platelet clumping  
-Similar gastro protective effects as  PGE2 
-Similar renal effects as  PGE2 
(Simmons, 2004; Osborn et al., 1984)  
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A clinical trial on rats showed that inhibition of both COX-1 and COX-2, putting a stop to all 
the protective factors of especially PGE2, is needed in order to induce NSAIDs related gastric 
injury (Wallace et al., 2000). This indicates that COXIBs would be related with less 
gastrointestinal adverse effects, however according to Innes et al. (2010a), it hasn’t yet been 
scientifically proven in veterinary medicine. 
Kidneys 
The kidney is the organ receiving the second highest reports of adverse events associated with 
use of NSAID’s. Furthermore, no NSAID has proven safe for the kidney. The decreased 
prostanoids synthesis (especially the one of PGE2) followed by NSAIDs usage, shows in the 
kidney as decreased RBF (volume of blood delivered to the kidney per unit of time) and/or GFR 
(volume of fluid filtered by the kidneys per unit of time). The decreased excretion of sodium 
and water increase the risk for oedema and hypertension and in the event of severe cases, 
NSAID usage could lead to acute kidney injury (AKI) (Lomas & Grauer, 2015). 
Both COX-1 and COX-2 are expressed in the renal of dogs, however Radi (2009) presented 
information showing significant interspecies differences in distribution and presence of the two. 
Basal levels of COX-2 is significantly higher in dogs than other species such as humans and 
monkeys. A study was carried out by Sellers et al. (2005) where dogs and monkeys were given 
a nonspecific COX-inhibitor for two to six weeks to compare the differences in COX-
expression between the two. The study showed that although the reduction in renal 
prostaglandin levels were similar between the two groups, a higher level of renal toxicity 
showed by decreased urine output and sodium excretion, was present amongst the dogs. This 
probably due to greater inhibition of COX-2 in the dogs hence possibly making them more 
sensitive to COXIBs. 
Hypersensitivity and behavioural changes 
Different species have demonstrated COX-1 versus COX-2 sensitivity to varying extents and 
the relative safety of one NSAIDs for a species cannot be automatically be translated as safe to 
another (Innes et al., 2010a). According to the package insert for dogs Loxicom® (Norbrook 
Laboratories Limited), there is an individual hypersensitivity which must be assessed case by 
case and in addition to the direct adverse effects, individuals can exhibit behavioural changes 
such as lethargy and depression. 
Drug-drug interactions and long-term treatment 
As mentioned before, NSAIDs can cause kidney disease and concurrent treatment with other 
nephrotoxic drugs, such as aminoglycosides, is a risk factor. NSAIDs also have effect in the 
treatment of hypertension, lowering the effect of ACE-inhibitors and beta blockers in humans. 
Furthermore a treatment containing both NSAIDs and corticosteroids increases the risk of 
gastrointestinal- and nephrotoxic injuries and has negative impact on platelet function in dogs 
(KuKanich et al., 2012). 
Concurrent treatment with different NSAIDs increases the risk of especially gastrointestinal 
damage and therefor a washout period is recommended if changing from one NSAID to another 
(KuKanich et al., 2012). 
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Recommendations regarding treatment of osteoarthritis using NSAIDs varies from intermittent 
to continuous, so called long-term treatment, depending on the author. The potential risks of 
long-term treatment include dogs developing drug tolerance over time and an increased 
incidence of adverse effects associated with NSAIDs (Innes et al., 2010a). 
Innes et al. (2010a) further believe it is most likely the perception of the risk of adverse events 
that restricts NSAIDs long time use. There are no exact and controlled estimates for the 
incidence of adverse events with long-term use in large numbers of dogs (Innes et al., 2010a; 
Innes et al., 2010b). Lomas and Grauer (2015) share the view that NSAIDs are often used for 
chronic management of osteoarthritis, although few long-term safety studies exist. 
A chronic use of NSAIDs is unfavourable to dogs with concurrent disease such as liver- and 
renal disease, heart failure, volume depletion, hypotension and sodium depletion (KuKanich et 
al., 2012). This complicates and create restrictions on treatment, especially in older dogs who 
tend to suffer from more illnesses over time. One example is chronic kidney disease (CKD) 
that, just as osteoarthritis, increases with age. This makes it likely to believe that many dogs 
will have an early stage CKD as being treated with NSAIDs for osteoarthritis. As CKD can 
decrease renal perfusion when nephrons are lost, the kidney becomes more dependent on COX-
2 production of prostanoids to remain fluid balance and RBF (Lomas & Grauer, 2015). 
Disease-modifying osteoarthritis agents 
In order to move forward with the medical treatment of osteoarthritis in dogs, research has been 
developing alternative treatment methods. Disease modifying osteoarthritis agents focus on 
slowing down the progression of cartilage degradation and promote cartilage matrix synthesis. 
Despite poorly satisfying scientific studies validating their efficacy, the so called slow-acting 
disease modifying osteoarthritis agents, are frequently used today. They can further be divided 
into parenterally products and orally administered products (McLaughlin, 2000). 
Glucosamine- and chondroitin sulphate 
Henrotin et al. (2005) presented glucosamine- and chondroitin sulphate as the main examples 
of nutraceuticals in the management of canine osteoarthritis. Stating they have improved 
symptomatic as well as structural characteristics of osteoarthritis in both animals and humans. 
However this is a well-debated topic facing many opponents with sceptical attitude towards its 
efficiency in dogs (Moreau et al., 2003). Furthermore no scientific trials have been carried out 
to demonstrate the disease modifying properties on dogs (Henrotin et al., 2005). 
Mechanism of action 
The cartilage matrix (ECM) is divided into collagen, proteoglycans and water, and disturbances 
in distribution between these, play part in changes typically associated with osteoarthritis 
(Johnston, 1997). 
Proteoglycans constitute the biggest part of the ECM and is made up of a core protein to which 
several types of glycosaminoglycan (GAG) chains are attached (Johnston, 1997). Glucosamine 
(GS) is an amino-monosaccharide and a precursor in the GAG-synthesis in the ECM and 
synovial fluid (Elliot et al., 2007). Dogs have shown to absorb 87% of the GS administered in 
the gastrointestinal tract and by synthetically adding GS, core proteins are said to be activated 
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and the proteoglycan synthesis is stimulated in order to achieve structure modifying properties. 
(Elliot et al., 2007; Setnikar et al., 1986). A study made in vitro by Bassleer et al. (1998) showed 
that GS and chondroitin sulphate (CS) increased the production of proteoglycans in human 
articular chondrocytes.  
Chondroitin sulphate (CS) in turn is one of the most common GAG in articular cartilage 
(Johnston, 1997). These are said to operate by providing additional substrate for proteoglycan 
synthesis (Elliot et al., 2007) 
Few studies have been carried out on dogs but in a human in vitro study, Largo et al. (2003) 
investigated the possibility that GS also possess anti-inflammatory hence pain relieving 
abilities. The study showed amongst other, that GS inhibit PGE2 synthesis through inhibition of 
IL-1 induced COX-2. The scientific knowledge regarding the mechanism of action of these 
nutraceuticals is however yet to be fully discovered (Largo et al., 2003). 
Adverse events 
The safety profile for GS has been estimated as excellent over time. In a systemic review by 
Anderson et al. (2005), more than seventeen studies on animals including rats, mice, rabbits, 
dogs and horses, were evaluated based on acute-, sub-chronic- and chronic toxicity. The studies 
ranged from twelve to three hundred and sixty-five days. It was concluded that oral GS appears 
to be well tolerated by rats, mice, rabbits, dogs and horses. Although Henrotin et al. (2005) 
have reported some, on the rare occurrence, adverse effects from a human systemic review. 
Seven out of one thousand and eighty-six patents randomized to GS had to be withdrawn from 
the study due to GS-related toxicity and forty-eight reported GS-related adverse effects. They 
predominantly regarded the gastrointestinal tract and went away as the patient went of GS. 
Efficacy NSAIDs vs glucosamine- and chondroitin sulphate 
In a study conducted by Moreau et al. (2003) the effects of two different NSAIDs (carprofen 
and meloxicam) were compared with a combined treatment of glucosamine, chondroitin 
sulphate and manganese ascorbate for sixty days. A total of seventy-one dogs with osteoarthritis 
participated and they were divided into four groups, the fourth being a placebo group. The 
results were measured by an objective gait analysis and a subjective observation carried out by 
the owners and the orthopaedic surgeons. Dogs treated with NSAIDs showed significant 
improvements objectively and subjectively while dogs treated with nutraceuticals, did not show 
any improvements. However, a dog treated with carprofen showed adverse effects in form of 
hepatopathy at the end of the study. Furthermore, two dogs in the NSAIDs treatment group had 
to withdraw before the end of the study due to adverse effects. One showing clinical signs of 
vomiting and the other being diagnosed with toxic idiosyncratic hepatitis to carprofen. 
In another study carried out by McCarthy et al. (2007), forty-two dogs with confirmed 
osteoarthritis were divided into two treatment groups; glucosamine- and chondroitin sulphate 
(Glu/Cs) and a positive control group (carprofen). After seventy days of treatment, thirty-five 
dogs remained (two had to withdraw due to adverse effects, both from the Glu/Cs treatment 
group). The result, based on subjective evaluation by participating veterinarians, showed 
statistically significant improvements in scores for pain, weight bearing and severity of illness 
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in the Glu/Cs treatment group. However dogs treated with carprofen showed the same 
improvement on day forty-two of treatment. 
The two studies above present disagreeing results. One explanation could be that glucosamine- 
and chondroitin sulphate need more than sixty days to reach full efficiency and that the first 
trial might have administered a dose that was too low. Furthermore, the second study does not 
elaborate what side effects were seen in the two dogs being withdrawn from the study, making 
it harder to draw conclusions. Also, the second study did not have an objective measurement 
analysis possibly affecting the study result. 
Weight management in dogs with osteoarthritis 
Elliot et al. (2007) suggested that adjustments to achieve appropriate lifestyle, including weight 
reduction and suitable physical exercise, might be the most important aspect of therapy when it 
comes to clinically improve osteoarthritis. In this thesis, the importance of weight management 
will be addressed. 
Excess body weight contributes to increased mechanical stress on the joints, which is a risk 
factor for the development of osteoarthritis. In addition it is a contributing factor to increased 
stress on already tender joint, something that accelerate the disease progression (Elliot et al., 
2007; Rychel, 2010). Marshall et al. (2009) presented numbers from studies investigating the 
estimated prevalence of canine obesity to be 24% in 1986 and 41% in 2005, showing an 
increasing trend amongst domesticated dogs. 
Marshall et al. (2009) further developed that the relationship between obesity and osteoarthritis 
seem to involve both biomechanical and biochemical factors. Adipose tissue is said to have a 
role in biological processes mediated by the produced peptide hormone leptin. Leptin is said, 
amongst other, to inhibit the effect on long-term growth of cultured chondrocytes by inducing 
matrix metalloproteinases (MMPs) in dose-dependent manner and induce IL-1. 
A study carried out by Smith et al. (2006) evaluated the effect of lifelong food restriction and 
the development of radiographic evidence of osteoarthritis in hip joints in Labrador Retrievers. 
The study contained forty-eight dogs divided into two groups being control fed respectively 
restrictedly fed (which was 25% less) over fourteen years. The study showed that dogs in the 
restricted group had delayed or prevented development of radiographic osteoarthritis. The 
radiologist who scored the radiographs was not aware of which group the dog was part of. 
However the differences in exercise between the dogs were not controlled and the parents to 
the dogs were chosen by subjective criteria. 
Ethical aspect of osteoarthritic treatment in dogs 
According to the Swedish Medical Products Agency (2005), ”All chronic pain where the 
connection with incurable conditions where pain cannot be treated satisfactorily, ethical and 
animal welfare aspects must be taken into account and euthanasia in such cases should be 
considered in consultation with the animal's owner.” 
Today many dogs with osteoarthritis are treated but it is questionable if it is always ethically 
defensible. According to The Swedish Animal Welfare Act (SFS 1988:534), the animals are to 
be treated well and to be protected from unnecessary suffering continuing to be managed in 
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such a way that it promotes their health and allows them to behave naturally. The dog has a 
natural need for movement which is prevented to different degrees in osteoarthritis. Is it 
ethically defensible to continue treating dogs who can no longer perform their natural 
behaviour, along with being exposed to pain where analgesics might be inadequate and where 
to draw the line? 
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DISCUSSION 
Osteoarthritis is a complex condition associated with different degrees of pain and NSAIDs is 
the most common therapeutic treatment method today (Simmons, 2004). NSAIDs is thus to 
question because of its, in some cases, serious adverse effects. 
Although COXIBs are said to give less gastrointestinal adverse effects in dogs there are no 
published reports saying that these would also be associated with fewer adverse effects on the 
kidneys and liver (KuKanich et al., 2012). There are even indications that COXIBs could 
contribute to increased risk of renal toxicity in dogs though they seem to have more COX-2 
naturally expressed in parts of the kidneys (Sellers et al., 2005). 
There is also an existing uncertainty regarding the safety profile over time in dogs. There are 
few long-term studies on NSAID therapy and different therapists tend to give different 
treatment advice (Innes et al., 2010a). More research on the long-term effects of NSAIDs in 
dogs and furthermore research is also needed on COXIBs to see how toxic they are for the liver 
and kidneys. 
The prevalence of osteoarthritis increases with age, and this is a problem in older dogs because 
they also have an increased risk of other diseases. Dogs with other diseases related to the areas 
where NSAIDs related adverse effects are shown, are warned against treatment (KuKanich et 
al., 2012). This and the fact that concurrent treatment with corticosteroids, nephrotoxic drugs 
or other NSAIDs is associated with risks, might make it impossible to treat osteoarthritis with 
NSAIDs in some dogs. 
So there are several arguments for being sceptical to NSAIDs in the treatment of osteoarthritis 
in dogs. Another is whether or not treatment of only the pain is inadequate. Some argue that 
analgesic effect from NSAIDs potentially open up to the ability of increased physical mobility 
(Innes et al., 2010b). If that being true, it would be arguable that NSAIDs could contribute to 
secondary improved condition due to increased muscle mass around the joint (Innes et al., 
2010b). Another way of mediating joint repair is by stimulating ECM synthesis and thus relieve 
the pain in the long term, something that glucosamine- and chondroitin sulphate aim to do. 
Although glucosamine- and chondroitin sulphate are the most common nutraceuticals in the 
treatment of osteoarthritis in dogs, few scientific studies prove their efficacy. We need more 
research carried out on the dog to be able to draw conclusions about the disease modifying 
effects and further if their analgesic ability is adequate. In the studies being compared in this 
thesis, glucosamine- and chondroitin sulphate take longer time to reach analgesic effect and 
appear to have a generally poorer analgesic capacity compared with NSAIDs. 
Most likely there is no easy solution to the treatment of osteoarthritis. Johnston et al. (2008) 
said: "Because of the complex neurobiology of pain, it is reasonable to believe that multimodal 
pharmacologic and non-pharmacologic therapy is advantageous for the treatment of 
osteoarthritis." This statement makes a lot of sense in that different treatment methods seem to 
play different roles in the prevention of development as well as progression of osteoarthritis. 
Physical rehabilitation and weight management seem to have major impact mediating both. 
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As the treatment situation is today, it seems analgesia using NSAIDs is necessary from an 
ethical and animal welfare point of view. This as other treatment methods haven’t scientifically 
proven to reach the same analgesic effect. However, it is important to think about how far to go 
in the treatment of dogs with osteoarthritis and how much pain should be allowed. There is a 
risk that dog owners adapt a progressive mental tolerance regarding their dog’s condition. They 
might stop objectively comparing the state of their sick dog with the state of healthy dogs and 
settle with the degree of improvement that can be achieved with current treatments on the 
market. This, despite it possibly being nonsufficient from an ethical- and animal welfare 
perspective. 
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